PerkinElmer issues $2.3B in senior notes to finance BioLegend acquisition

REVVITY, INC.

Issued $2.3B aggregate: $500M 0.55% notes due 2023, $800M 0.85% due 2024, $500M 1.90% due 2028, $500M 2.25% due 2031.
Net proceeds ~$2.28B to partially fund $5.7B BioLegend acquisition announced July 25, 2021.
Special mandatory redemption at 101% if BioLegend deal not closed by Jan 31, 2022.
Bridge loan commitments reduced to $514M after net proceeds.
Notes are general unsecured, rank equally with other unsecured debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.